drug_type
RELEVANT_DRUG
intervention_type
Gene therapy (in vivo CAR-T vector)
drug_description
An in vivo CAR-T gene therapy vector (IV) that transduces the patient's autologous T cells to express a CD19-targeted chimeric antigen receptor, leading to recognition and killing of CD19+ B-cell malignancies; dose expressed in transduction units/kg.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Gene Therapy
drug_category
GENE THERAPY
drug_class
Gene therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Intravenous in vivo vector transduces the patient’s autologous T cells to express a CD19-targeted chimeric antigen receptor, creating CAR-T cells in situ that expand and, upon binding CD19 on malignant B cells, activate CAR signaling (CD3zeta/costimulation) to mediate cytotoxic killing independent of the native TCR.
drug_name
JY231 Injection
nct_id_drug_ref
NCT06678282